Literature DB >> 8725044

Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH).

S Dutkiewicz1, A Witeska, K Stepień.   

Abstract

The relationship between plasma PSA, prostatic adenoma mass (AM), retention volume (RV) and age was studied in 112 men with benign prostatic hypertrophy (BPH). Their age ranged from 48 to 85 years. Mean PSA was 6.9 ng/ml (SD 6.6) and did not exceed 10 ng/ml in 81.2% of the patients. Mean AM and RV were 66.2 g (SD 36) and 51.7 ml (SD 1.3), respectively. Increase in PSA level was influenced mainly by RV (r = 0.53) but was found to correlate weakly with AM (r = 0.34) which in turn showed low correlation with RV (r = 0.32). Age did not correlate with PSA, AM and RV (r > or = 0.1). AM and RV influence PSA levels independently and large inter-patient differences are well characterized by SD values.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8725044     DOI: 10.1007/BF02552144

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  11 in total

Review 1.  Prostatic specific antigen.

Authors:  R J Shearer
Journal:  Br J Urol       Date:  1991-01

2.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

3.  The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.

Authors:  T G Armitage; E H Cooper; D W Newling; M R Robinson; I Appleyard
Journal:  Br J Urol       Date:  1988-12

4.  The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.

Authors:  J P Weber; J E Oesterling; C A Peters; A W Partin; D W Chan; P C Walsh
Journal:  J Urol       Date:  1989-04       Impact factor: 7.450

5.  High prevalence of benign prostatic hypertrophy in the community.

Authors:  W M Garraway; G N Collins; R J Lee
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

Review 6.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.

Authors:  J E Oesterling
Journal:  J Urol       Date:  1991-05       Impact factor: 7.450

7.  Relationship between prostate specific antigen, prostate volume and age in the benign prostate.

Authors:  G N Collins; R J Lee; G B McKelvie; A C Rogers; M Hehir
Journal:  Br J Urol       Date:  1993-04

8.  The prognostic value of prostate-specific antigen and prostatic acid phosphatase in serum of patients with prostate cancer after orchidectomy.

Authors:  S Dutkiewicz; B Stawarz; A Lypka; H Zieliński
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

9.  [Diagnostic value of prostatic specific antigen (PSA) in comparison to prostatic acid phosphatase (PAP) in prostatic cancer and adenoma].

Authors:  S Dutkiewicz; K Stepień; A Witeska
Journal:  Wiad Lek       Date:  1992-10

10.  Prostate specific antigen in screening for recurrence following radical prostatectomy for localised prostatic cancer.

Authors:  F M Bentvelsen; D van den Ouden; F H Schröder
Journal:  Br J Urol       Date:  1993-07
View more
  2 in total

1.  Association between single nucleotide polymorphism of vitamin D receptor gene FokI polymorphism and clinical progress of benign prostatic hyperplasia.

Authors:  Li Ruan; Jian-guo Zhu; Cong Pan; Xing Hua; Dong-bo Yuan; Zheng-ming Li; Wei-de Zhong
Journal:  ScientificWorldJournal       Date:  2015-01-20

Review 2.  Deiodinases and Cancer.

Authors:  Annarita Nappi; Maria Angela De Stefano; Monica Dentice; Domenico Salvatore
Journal:  Endocrinology       Date:  2021-04-01       Impact factor: 4.736

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.